Literature DB >> 31632661

PRO: This Patient Should Have a Liver Biopsy.

Akshata Moghe1, Matthew Klinge1, Naudia Jonassaint1.   

Abstract

Entities:  

Year:  2019        PMID： 31632661      PMCID： PMC6784796          DOI： 10.1002/cld.824

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  13 in total

1.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

4.  Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

5.  Liver biopsy: is the pain for real or is it only the fear of it?

Authors:  Sinan Akay; Zeki Karasu; Aysin Noyan; Semanur Pala; Ahmet Musoglu; Tankut Ilter; Yucel Batur
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

6.  Low Rates of Gastrointestinal and Non-Gastrointestinal Complications for Screening or Surveillance Colonoscopies in a Population-Based Study.

Authors:  Louise Wang; Ajitha Mannalithara; Gurkirpal Singh; Uri Ladabaum
Journal:  Gastroenterology       Date:  2017-10-12       Impact factor: 22.682

Review 7.  Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Jennifer S Lin; Margaret A Piper; Leslie A Perdue; Carolyn M Rutter; Elizabeth M Webber; Elizabeth O'Connor; Ning Smith; Evelyn P Whitlock
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

8.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 9.  Elastography in Chronic Liver Disease: Modalities, Techniques, Limitations, and Future Directions.

Authors:  Aparna Srinivasa Babu; Michael L Wells; Oleg M Teytelboym; Justin E Mackey; Frank H Miller; Benjamin M Yeh; Richard L Ehman; Sudhakar K Venkatesh
Journal:  Radiographics       Date:  2016-09-30       Impact factor: 5.333

10.  Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

Authors:  Raj Vuppalanchi; Aynur Unalp; Mark L Van Natta; Oscar W Cummings; Kumar E Sandrasegaran; Tariq Hameed; James Tonascia; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2008-12-25       Impact factor: 11.382
View more
  1 in total

1.  Efficacy and safety of elbasvir/grazoprevir treatment for Chinese patients with hepatitis C virus genotype 1b: a retrospective study.

Authors:  Juan Li; Guangming Li; Juanxia Wang; Rui Zhao; Jingjing He; Liang Wang; Lingyi Zhang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.